Yelena Janjigian

Yelena Janjigian: Amgen Reports Positive Phase 3 Results for Bemarituzumab in FGFR2b+ Gastric Cancer

Yelena Janjigian, Chief of Gastrointestinal Oncology at Memorial Sloan Kettering Cancer Center, posted on LinkedIn:

“FGFR2B expression as a bookmaker in first line GEC.
Congratulations to all the investigators.”

Read Further.

Read Further: Oncologist Near Me – Yelena Janjigian: A Global Leader in Gastrointestinal Oncology.